Accuray Inc (ARAY)

4.05
0.15 3.85
NASDAQ : Health Care
Prev Close 3.90
Open 3.95
Day Low/High 3.90 / 4.15
52 Wk Low/High 4.75 / 7.54
Volume 776.18K
Avg Volume 513.50K
Exchange NASDAQ
Shares Outstanding 83.00M
Market Cap 336.15M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Accuray Receives 510(k) Clearance For IDMS™ Data Management System Upgrade For The TomoTherapy® System

Accuray Receives 510(k) Clearance For IDMS™ Data Management System Upgrade For The TomoTherapy® System

iDMS System Allows Seamless Integration between Accuray Radixact™, TomoTherapy® and CyberKnife® Systems and Treatment Planning Systems

Accuray Enhances Capital Structure Through Convertible Debt Transactions

Accuray Enhances Capital Structure Through Convertible Debt Transactions

­Transactions Facilitate Reduction of Short-term Debt and Potential Dilution to Shareholders

New Data Show TomoTherapy® System Superior To RapidArc In Achieving Local Control Of Head And Neck Cancers

New Data Show TomoTherapy® System Superior To RapidArc In Achieving Local Control Of Head And Neck Cancers

Prospective, Multicenter Study Supported by the French National Institute of Cancer Also Demonstrates that Treatment with the TomoTherapy Platform Resulted in a Significantly Better Cancer-Specific Survival Rate and Post-Treatment Salivary Function

Accuray Announces Preliminary Fourth Quarter And Fiscal Year 2017 Results

Accuray Announces Preliminary Fourth Quarter And Fiscal Year 2017 Results

Q4 Revenue Expected to be Approximately $111.5-$112 Million and Q4 Gross Orders Expected to be Approximately $86 Million; Accuray Expects to Finish Fiscal Year with Approximately $108 Million in Cash, Cash Equivalents & Investments

Neuro Spinal Hospital In Dubai To Acquire Accuray CyberKnife® And Radixact™ Systems

Neuro Spinal Hospital In Dubai To Acquire Accuray CyberKnife® And Radixact™ Systems

Leading Hospital will be the First in the Middle East to Offer Patients Precise Treatments with the Latest Generations of Both Systems

Montefiore Is First In NY Metropolitan Area To Treat Cancer Patients With Accuray Radixact™ System

Cutting-Edge Radiation Therapy System Dramatically Improves Precision, Efficiency and Safety, While Minimizing Side Effects

IUCT Oncopole Advances Cancer Care In France With The New Accuray Radixact™ System

The French Cancer Institute is Building its Re-irradiation and Adaptive Radiotherapy Program Using the Latest Technology Developed by Accuray

Anova Marks 1,500th Prostate Cancer Patient Treated With The Accuray CyberKnife® System

- Accuray and Anova Cancer Care Remember Prostate Patients this Father's Day

Accuray Enters Into New Revolving Loan Agreement

New Loan Expected to Reduce Interest Costs by Approximately $2.0 Million Annually

New Data Reinforce Benefits Of TomoTherapy® Platform For Mainstream Radiation Therapy Treatment Indications

Multiple Studies Presented at ESTRO 36 Demonstrate System Improves Tumor Control withReduced Toxicities

New Data Presented At ESTRO 36 Reinforce Unmatched Versatility And Precision Of The CyberKnife® System

Studies Show the System Provides Excellent Outcomes Throughout the Cancer Treatment Journey, from Primary Cases to Recurrence and Metastatic Disease

Accuray To Showcase CyberKnife® And Radixact™ Systems At ESTRO 2017

Innovations in Hardware and Software Solutions Reinforce the Benefits of Accuray Systems in Treating a Wide Range of Cancer Cases

Accuray Enters Oversold Territory (ARAY)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

CyberKnife® System Provides Effective Treatment Option With Minimal Side Effects And Excellent Cosmesis For Early Stage Breast Cancer Patients

Robotic Radiosurgery System's Unique Motion Management Technique Limits Toxicity and Preserves Cosmesis in Convenient, 5-Fraction Treatment Regimen

First Cancer Patients In Africa Treated With The TomoTherapy® System

Premier Algerian Cancer Center Now Provides Cancer Patients with Leading-Edge Radiation Treatments

CyberKnife® System Provides Long-term Disease Control For Prostate Cancer Patients

Prospective, Multi-institutional Study Shows CyberKnife SBRT Treatment Results in Low PSA Nadir for Low- and Intermediate-risk Prostate Cancer Patients

First Week of ARAY September 15th Options Trading

First Week of ARAY September 15th Options Trading

Investors in Accuray Inc saw new options begin trading this week, for the September 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Accuray Continues To Set The Industry Standard For Customer Satisfaction

Accuray Continues To Set The Industry Standard For Customer Satisfaction

MD Buyline Report Shows Composite Overall User Satisfaction Ratings Exceed Industry Average for 14 Consecutive Quarters

Short Interest Moves 12.7% Lower For ARAY

Short Interest Moves 12.7% Lower For ARAY

The most recent short interest data has been released for the 12/30/2016 settlement date, which shows a 963,627 share decrease in total short interest for Accuray Inc , to 6,615,663, a decrease of 12.71% since 12/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Investors eyeing a purchase of Accuray Inc shares, but cautious about paying the going market price of $5.08/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2017 put at the $4 strike, which has a bid at the time of this writing of 25 cents.

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Investors eyeing a purchase of Accuray Inc shares, but cautious about paying the going market price of $5.08/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2017 put at the $4 strike, which has a bid at the time of this writing of 25 cents.

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Commit To Buy Accuray At $4, Earn 11.6% Annualized Using Options

Investors eyeing a purchase of Accuray Inc shares, but cautious about paying the going market price of $5.08/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2017 put at the $4 strike, which has a bid at the time of this writing of 25 cents.

Accuray (ARAY) Stock Sharply Lower After Q4 Results, Guidance

Accuray (ARAY) Stock Sharply Lower After Q4 Results, Guidance

Accuray (ARAY) reported a larger-than-anticipated loss for the 2016 fiscal fourth quarter and a downbeat forecast following Wednesday's closing bell.

Will Accuray (ARAY) Stock Fall on Q4 Miss, Downbeat Outlook?

Will Accuray (ARAY) Stock Fall on Q4 Miss, Downbeat Outlook?

Accuray (ARAY) posted a wider-than-expected loss for the 2016 fiscal fourth quarter after Wednesday's market close.

Trade These 5 Biotech Breakouts Now for Big Gains

Trade These 5 Biotech Breakouts Now for Big Gains

Here's a technical look at how to trade five biotech stocks that are setting up to break out and trade much higher.